proteintech cat no 16616 1 ap Search Results


anti lag3  (Proteintech)
93
Proteintech anti lag3
Anti Lag3, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteintech+cat+no+16616+1+ap/LAG-3+Antibody/10__4103_slash_nrr__nrr___d___24___00941-125-91-95
Average 93 stars, based on 1 article reviews
anti lag3 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
anti cd4 antibody  (Proteintech)
96
Proteintech anti cd4 antibody
MIAT correlates with CD8 + T-cell exhaustion and poor response to immunotherapy in RCC. ( A ) Correlation between the expression level of MIAT and several CD8 + T-cell exhaustion markers including PD-1, LAG3 and TIGIT in TCGA-KIRC cohort. ( B ) IHC assays showed that PD-1, LAG3 and TIGIT were notably overexpressed in MIAT-high expression group in our own RCC cohort. ( C ) IHC assays showed that there was no difference in CD8 + and <t>CD4</t> + T-cell infiltration levels between MIAT-high and MIAT-low groups. ( D ) Survival analysis showed that lower expression level of MIAT was associated with better response to immunotherapy in patients with RCC. ns, not significant, *p<0.05, ***p<0.001. IHC, immunohistochemistry; LAG3, lymphocyte activation gene-3; MIAT, myocardial infarction associated transcript; PD-1, programmed cell death protein 1; RCC, renal cell carcinoma; TCGA-KIRC, The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; TPM, transcripts per million.
Anti Cd4 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteintech+cat+no+16616+1+ap/CD4+Antibody/pmc12314945-112-37-39
Average 96 stars, based on 1 article reviews
anti cd4 antibody - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
anti cd8 antibody  (Proteintech)
96
Proteintech anti cd8 antibody
MIAT correlates with <t>CD8</t> + T-cell exhaustion and poor response to immunotherapy in RCC. ( A ) Correlation between the expression level of MIAT and several CD8 + T-cell exhaustion markers including PD-1, LAG3 and TIGIT in TCGA-KIRC cohort. ( B ) IHC assays showed that PD-1, LAG3 and TIGIT were notably overexpressed in MIAT-high expression group in our own RCC cohort. ( C ) IHC assays showed that there was no difference in CD8 + and CD4 + T-cell infiltration levels between MIAT-high and MIAT-low groups. ( D ) Survival analysis showed that lower expression level of MIAT was associated with better response to immunotherapy in patients with RCC. ns, not significant, *p<0.05, ***p<0.001. IHC, immunohistochemistry; LAG3, lymphocyte activation gene-3; MIAT, myocardial infarction associated transcript; PD-1, programmed cell death protein 1; RCC, renal cell carcinoma; TCGA-KIRC, The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; TPM, transcripts per million.
Anti Cd8 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteintech+cat+no+16616+1+ap/CD8+Antibody/pmc12314945-112-31-33
Average 96 stars, based on 1 article reviews
anti cd8 antibody - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier

Image Search Results


MIAT correlates with CD8 + T-cell exhaustion and poor response to immunotherapy in RCC. ( A ) Correlation between the expression level of MIAT and several CD8 + T-cell exhaustion markers including PD-1, LAG3 and TIGIT in TCGA-KIRC cohort. ( B ) IHC assays showed that PD-1, LAG3 and TIGIT were notably overexpressed in MIAT-high expression group in our own RCC cohort. ( C ) IHC assays showed that there was no difference in CD8 + and CD4 + T-cell infiltration levels between MIAT-high and MIAT-low groups. ( D ) Survival analysis showed that lower expression level of MIAT was associated with better response to immunotherapy in patients with RCC. ns, not significant, *p<0.05, ***p<0.001. IHC, immunohistochemistry; LAG3, lymphocyte activation gene-3; MIAT, myocardial infarction associated transcript; PD-1, programmed cell death protein 1; RCC, renal cell carcinoma; TCGA-KIRC, The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; TPM, transcripts per million.

Journal: Journal for Immunotherapy of Cancer

Article Title: MIAT promotes tumor-infiltrating CD8+ T-cell exhaustion and malignant progression of renal cell carcinoma via activating JAK3/STAT3 pathway

doi: 10.1136/jitc-2024-011162

Figure Lengend Snippet: MIAT correlates with CD8 + T-cell exhaustion and poor response to immunotherapy in RCC. ( A ) Correlation between the expression level of MIAT and several CD8 + T-cell exhaustion markers including PD-1, LAG3 and TIGIT in TCGA-KIRC cohort. ( B ) IHC assays showed that PD-1, LAG3 and TIGIT were notably overexpressed in MIAT-high expression group in our own RCC cohort. ( C ) IHC assays showed that there was no difference in CD8 + and CD4 + T-cell infiltration levels between MIAT-high and MIAT-low groups. ( D ) Survival analysis showed that lower expression level of MIAT was associated with better response to immunotherapy in patients with RCC. ns, not significant, *p<0.05, ***p<0.001. IHC, immunohistochemistry; LAG3, lymphocyte activation gene-3; MIAT, myocardial infarction associated transcript; PD-1, programmed cell death protein 1; RCC, renal cell carcinoma; TCGA-KIRC, The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; TPM, transcripts per million.

Article Snippet: Then, the sections were treated overnight at 4°C with the following primary antibodies: anti-PD-1 antibody (Abcam, catalog number: ab52587), anti-LAG3 antibody (Proteintech, catalog number: 16616–1-AP), anti-TIGIT antibody (Abcam, catalog number: ab243903), anti-CD8 antibody (Proteintech, catalog number: 66868–1-Ig), anti-CD4 antibody (Proteintech, catalog number: 67786–1-Ig) and anti-JAK3 antibody (Abcam, catalog number: ab45141).

Techniques: Expressing, Immunohistochemistry, Activation Assay

MIAT expression is associated with the dynamic changes and status of CD8 + T cells. ( A ) UMAP plot of annotated major cell types based on specific marker genes. ( B ) Bubble plot showing highly expressed marker genes in each major cell type, with cell types in rows and genes in columns. Size of each bubble represents per cent of cells expressing markers and color represents the level of expression. ( C ) A UMAP displaying the subclusters of T cells and NK cells. ( D ) Bubble plot showing the expression of lineage markers for each T cell and NK cell subcluster. ( E, F ) Comparison of CD8 + T-cell exhaustion score ( E ) and cytotoxic score ( F ) between high and low MIAT expression subgroups estimated by the “AddModuleScore” function in Seurat . Data are presented as mean±SD. ( G ) Histogram showing the proportions of seven types of immune cells with high or low MIAT expression levels. ( H ) Differentiation trajectory of CD8 + T cells, colored for pseudotime, MIAT expression, and cell types. ***p<0.001. MIAT, myocardial infarction associated transcript; NK, natural killer; Teff, effector CD8 + T cells; Tex, exhausted CD8 + T cells; Tn, naive CD4 + T cells; Tpro, proliferating CD8 + T cells; Treg, regulatory CD4 + T cells; UMAP, uniform manifold approximation and projection.

Journal: Journal for Immunotherapy of Cancer

Article Title: MIAT promotes tumor-infiltrating CD8+ T-cell exhaustion and malignant progression of renal cell carcinoma via activating JAK3/STAT3 pathway

doi: 10.1136/jitc-2024-011162

Figure Lengend Snippet: MIAT expression is associated with the dynamic changes and status of CD8 + T cells. ( A ) UMAP plot of annotated major cell types based on specific marker genes. ( B ) Bubble plot showing highly expressed marker genes in each major cell type, with cell types in rows and genes in columns. Size of each bubble represents per cent of cells expressing markers and color represents the level of expression. ( C ) A UMAP displaying the subclusters of T cells and NK cells. ( D ) Bubble plot showing the expression of lineage markers for each T cell and NK cell subcluster. ( E, F ) Comparison of CD8 + T-cell exhaustion score ( E ) and cytotoxic score ( F ) between high and low MIAT expression subgroups estimated by the “AddModuleScore” function in Seurat . Data are presented as mean±SD. ( G ) Histogram showing the proportions of seven types of immune cells with high or low MIAT expression levels. ( H ) Differentiation trajectory of CD8 + T cells, colored for pseudotime, MIAT expression, and cell types. ***p<0.001. MIAT, myocardial infarction associated transcript; NK, natural killer; Teff, effector CD8 + T cells; Tex, exhausted CD8 + T cells; Tn, naive CD4 + T cells; Tpro, proliferating CD8 + T cells; Treg, regulatory CD4 + T cells; UMAP, uniform manifold approximation and projection.

Article Snippet: Then, the sections were treated overnight at 4°C with the following primary antibodies: anti-PD-1 antibody (Abcam, catalog number: ab52587), anti-LAG3 antibody (Proteintech, catalog number: 16616–1-AP), anti-TIGIT antibody (Abcam, catalog number: ab243903), anti-CD8 antibody (Proteintech, catalog number: 66868–1-Ig), anti-CD4 antibody (Proteintech, catalog number: 67786–1-Ig) and anti-JAK3 antibody (Abcam, catalog number: ab45141).

Techniques: Expressing, Marker, Comparison

MIAT correlates with CD8 + T-cell exhaustion and poor response to immunotherapy in RCC. ( A ) Correlation between the expression level of MIAT and several CD8 + T-cell exhaustion markers including PD-1, LAG3 and TIGIT in TCGA-KIRC cohort. ( B ) IHC assays showed that PD-1, LAG3 and TIGIT were notably overexpressed in MIAT-high expression group in our own RCC cohort. ( C ) IHC assays showed that there was no difference in CD8 + and CD4 + T-cell infiltration levels between MIAT-high and MIAT-low groups. ( D ) Survival analysis showed that lower expression level of MIAT was associated with better response to immunotherapy in patients with RCC. ns, not significant, *p<0.05, ***p<0.001. IHC, immunohistochemistry; LAG3, lymphocyte activation gene-3; MIAT, myocardial infarction associated transcript; PD-1, programmed cell death protein 1; RCC, renal cell carcinoma; TCGA-KIRC, The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; TPM, transcripts per million.

Journal: Journal for Immunotherapy of Cancer

Article Title: MIAT promotes tumor-infiltrating CD8+ T-cell exhaustion and malignant progression of renal cell carcinoma via activating JAK3/STAT3 pathway

doi: 10.1136/jitc-2024-011162

Figure Lengend Snippet: MIAT correlates with CD8 + T-cell exhaustion and poor response to immunotherapy in RCC. ( A ) Correlation between the expression level of MIAT and several CD8 + T-cell exhaustion markers including PD-1, LAG3 and TIGIT in TCGA-KIRC cohort. ( B ) IHC assays showed that PD-1, LAG3 and TIGIT were notably overexpressed in MIAT-high expression group in our own RCC cohort. ( C ) IHC assays showed that there was no difference in CD8 + and CD4 + T-cell infiltration levels between MIAT-high and MIAT-low groups. ( D ) Survival analysis showed that lower expression level of MIAT was associated with better response to immunotherapy in patients with RCC. ns, not significant, *p<0.05, ***p<0.001. IHC, immunohistochemistry; LAG3, lymphocyte activation gene-3; MIAT, myocardial infarction associated transcript; PD-1, programmed cell death protein 1; RCC, renal cell carcinoma; TCGA-KIRC, The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; TPM, transcripts per million.

Article Snippet: Then, the sections were treated overnight at 4°C with the following primary antibodies: anti-PD-1 antibody (Abcam, catalog number: ab52587), anti-LAG3 antibody (Proteintech, catalog number: 16616–1-AP), anti-TIGIT antibody (Abcam, catalog number: ab243903), anti-CD8 antibody (Proteintech, catalog number: 66868–1-Ig), anti-CD4 antibody (Proteintech, catalog number: 67786–1-Ig) and anti-JAK3 antibody (Abcam, catalog number: ab45141).

Techniques: Expressing, Immunohistochemistry, Activation Assay

MIAT expression is associated with the dynamic changes and status of CD8 + T cells. ( A ) UMAP plot of annotated major cell types based on specific marker genes. ( B ) Bubble plot showing highly expressed marker genes in each major cell type, with cell types in rows and genes in columns. Size of each bubble represents per cent of cells expressing markers and color represents the level of expression. ( C ) A UMAP displaying the subclusters of T cells and NK cells. ( D ) Bubble plot showing the expression of lineage markers for each T cell and NK cell subcluster. ( E, F ) Comparison of CD8 + T-cell exhaustion score ( E ) and cytotoxic score ( F ) between high and low MIAT expression subgroups estimated by the “AddModuleScore” function in Seurat . Data are presented as mean±SD. ( G ) Histogram showing the proportions of seven types of immune cells with high or low MIAT expression levels. ( H ) Differentiation trajectory of CD8 + T cells, colored for pseudotime, MIAT expression, and cell types. ***p<0.001. MIAT, myocardial infarction associated transcript; NK, natural killer; Teff, effector CD8 + T cells; Tex, exhausted CD8 + T cells; Tn, naive CD4 + T cells; Tpro, proliferating CD8 + T cells; Treg, regulatory CD4 + T cells; UMAP, uniform manifold approximation and projection.

Journal: Journal for Immunotherapy of Cancer

Article Title: MIAT promotes tumor-infiltrating CD8+ T-cell exhaustion and malignant progression of renal cell carcinoma via activating JAK3/STAT3 pathway

doi: 10.1136/jitc-2024-011162

Figure Lengend Snippet: MIAT expression is associated with the dynamic changes and status of CD8 + T cells. ( A ) UMAP plot of annotated major cell types based on specific marker genes. ( B ) Bubble plot showing highly expressed marker genes in each major cell type, with cell types in rows and genes in columns. Size of each bubble represents per cent of cells expressing markers and color represents the level of expression. ( C ) A UMAP displaying the subclusters of T cells and NK cells. ( D ) Bubble plot showing the expression of lineage markers for each T cell and NK cell subcluster. ( E, F ) Comparison of CD8 + T-cell exhaustion score ( E ) and cytotoxic score ( F ) between high and low MIAT expression subgroups estimated by the “AddModuleScore” function in Seurat . Data are presented as mean±SD. ( G ) Histogram showing the proportions of seven types of immune cells with high or low MIAT expression levels. ( H ) Differentiation trajectory of CD8 + T cells, colored for pseudotime, MIAT expression, and cell types. ***p<0.001. MIAT, myocardial infarction associated transcript; NK, natural killer; Teff, effector CD8 + T cells; Tex, exhausted CD8 + T cells; Tn, naive CD4 + T cells; Tpro, proliferating CD8 + T cells; Treg, regulatory CD4 + T cells; UMAP, uniform manifold approximation and projection.

Article Snippet: Then, the sections were treated overnight at 4°C with the following primary antibodies: anti-PD-1 antibody (Abcam, catalog number: ab52587), anti-LAG3 antibody (Proteintech, catalog number: 16616–1-AP), anti-TIGIT antibody (Abcam, catalog number: ab243903), anti-CD8 antibody (Proteintech, catalog number: 66868–1-Ig), anti-CD4 antibody (Proteintech, catalog number: 67786–1-Ig) and anti-JAK3 antibody (Abcam, catalog number: ab45141).

Techniques: Expressing, Marker, Comparison

Silencing MIAT in RCC cells suppresses CD8 + T-cell exhaustion. ( A ) MIAT expression levels in HK2 and different RCC cell lines. ( B ) MIAT was silenced in 769-P and 786-O cells by two different short hairpin RNAs, respectively. ( C ) T-cell co-culture assays showed that silencing MIAT in RCC cells markedly increased the proportion of CD45RA − CCR7 − effector memory T cells. Naive (naive CD8 + T cell, CD8 + Tn, CD45RA + CCR7 + ), CM (central memory CD8 + T cell, CD8 + Tcm, CD45RA − CCR7 + ), EM (effector memory CD8 + T cell, CD8 + Tem, CD45RA − CCR7 − ), and TDE (terminally differentiated effector memory CD8 + T cell, Temra, CD45RA + CCR7 − ). ( D ) IFN-γ expression of live CD8 + T cells in different groups. ( E, F ) MIAT-siRNA markedly inhibited xenograft tumor growth. The tumor growth rate of different groups was shown in E. The images of gross tumors (left panel) and tumor weight (right panel) were shown in F. ( G ) The change of CD8 + T-cell differentiation on MIAT-siRNA treatment. ( H ) Perforin and IFN-γ expression of live CD8 + T cells in different groups. ( I ) PD-1 and TIGIT expression of live CD8 + T cells in different groups. ns, not significant, *p<0.05, **p<0.01, ***p<0.001. APC, allophycocyanin; IFN, interferon; MFI, mean fluorescence intensity; MIAT, myocardial infarction associated transcript; PD-1, programmed cell death protein 1; PE, phycoerythrin; RCC, renal cell carcinoma; siRNA, small interfering ribonucleic acid; TIGIT, T-cell immunoreceptor with Ig and ITIM domains.

Journal: Journal for Immunotherapy of Cancer

Article Title: MIAT promotes tumor-infiltrating CD8+ T-cell exhaustion and malignant progression of renal cell carcinoma via activating JAK3/STAT3 pathway

doi: 10.1136/jitc-2024-011162

Figure Lengend Snippet: Silencing MIAT in RCC cells suppresses CD8 + T-cell exhaustion. ( A ) MIAT expression levels in HK2 and different RCC cell lines. ( B ) MIAT was silenced in 769-P and 786-O cells by two different short hairpin RNAs, respectively. ( C ) T-cell co-culture assays showed that silencing MIAT in RCC cells markedly increased the proportion of CD45RA − CCR7 − effector memory T cells. Naive (naive CD8 + T cell, CD8 + Tn, CD45RA + CCR7 + ), CM (central memory CD8 + T cell, CD8 + Tcm, CD45RA − CCR7 + ), EM (effector memory CD8 + T cell, CD8 + Tem, CD45RA − CCR7 − ), and TDE (terminally differentiated effector memory CD8 + T cell, Temra, CD45RA + CCR7 − ). ( D ) IFN-γ expression of live CD8 + T cells in different groups. ( E, F ) MIAT-siRNA markedly inhibited xenograft tumor growth. The tumor growth rate of different groups was shown in E. The images of gross tumors (left panel) and tumor weight (right panel) were shown in F. ( G ) The change of CD8 + T-cell differentiation on MIAT-siRNA treatment. ( H ) Perforin and IFN-γ expression of live CD8 + T cells in different groups. ( I ) PD-1 and TIGIT expression of live CD8 + T cells in different groups. ns, not significant, *p<0.05, **p<0.01, ***p<0.001. APC, allophycocyanin; IFN, interferon; MFI, mean fluorescence intensity; MIAT, myocardial infarction associated transcript; PD-1, programmed cell death protein 1; PE, phycoerythrin; RCC, renal cell carcinoma; siRNA, small interfering ribonucleic acid; TIGIT, T-cell immunoreceptor with Ig and ITIM domains.

Article Snippet: Then, the sections were treated overnight at 4°C with the following primary antibodies: anti-PD-1 antibody (Abcam, catalog number: ab52587), anti-LAG3 antibody (Proteintech, catalog number: 16616–1-AP), anti-TIGIT antibody (Abcam, catalog number: ab243903), anti-CD8 antibody (Proteintech, catalog number: 66868–1-Ig), anti-CD4 antibody (Proteintech, catalog number: 67786–1-Ig) and anti-JAK3 antibody (Abcam, catalog number: ab45141).

Techniques: Expressing, Co-Culture Assay, Cell Differentiation, Fluorescence

MIAT exerts oncogenic roles via enhancing JAK3 expression. ( A ) T-cell co-culture assay revealed that JAK3 overexpression largely abrogated MIAT knockdown-induced increased IFN-γ secretion of CD8 + T cells. ( B, C ) CCK8 assays showed that JAK3 overexpression markedly abolished MIAT knockdown-induced suppression of proliferation ability of RCC cells. ( D, E ) Transwell assays showed that JAK3 overexpression largely abrogated suppression of migration and invasion abilities of RCC cells led by MIAT silencing. *p<0.05, **p<0.01, ***p<0.001. IFN, interferon; JAK3, janus kinase 3; MIAT, myocardial infarction associated transcript; PE, phycoerythrin; RCC, renal cell carcinoma.

Journal: Journal for Immunotherapy of Cancer

Article Title: MIAT promotes tumor-infiltrating CD8+ T-cell exhaustion and malignant progression of renal cell carcinoma via activating JAK3/STAT3 pathway

doi: 10.1136/jitc-2024-011162

Figure Lengend Snippet: MIAT exerts oncogenic roles via enhancing JAK3 expression. ( A ) T-cell co-culture assay revealed that JAK3 overexpression largely abrogated MIAT knockdown-induced increased IFN-γ secretion of CD8 + T cells. ( B, C ) CCK8 assays showed that JAK3 overexpression markedly abolished MIAT knockdown-induced suppression of proliferation ability of RCC cells. ( D, E ) Transwell assays showed that JAK3 overexpression largely abrogated suppression of migration and invasion abilities of RCC cells led by MIAT silencing. *p<0.05, **p<0.01, ***p<0.001. IFN, interferon; JAK3, janus kinase 3; MIAT, myocardial infarction associated transcript; PE, phycoerythrin; RCC, renal cell carcinoma.

Article Snippet: Then, the sections were treated overnight at 4°C with the following primary antibodies: anti-PD-1 antibody (Abcam, catalog number: ab52587), anti-LAG3 antibody (Proteintech, catalog number: 16616–1-AP), anti-TIGIT antibody (Abcam, catalog number: ab243903), anti-CD8 antibody (Proteintech, catalog number: 66868–1-Ig), anti-CD4 antibody (Proteintech, catalog number: 67786–1-Ig) and anti-JAK3 antibody (Abcam, catalog number: ab45141).

Techniques: Expressing, Co-culture Assay, Over Expression, Knockdown, Migration